What is the typical dosing regimen for Skyrizi?
Skyrizi, also known as risankizumab, is a humanized IgG1 monoclonal antibody that targets interleukin-23 (IL-23) for the treatment of various inflammatory and autoimmune diseases, including psoriasis and Crohn's disease. The dosing regimen for Skyrizi is typically as follows:
* For the treatment of moderate to severe plaque psoriasis, the recommended dose is 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter. [1]
* For the treatment of Crohn's disease, the recommended dose is 100 mg administered subcutaneously at weeks 0, 2, and 4, and every 8 weeks thereafter. [2]
How does the dosing regimen compare to other biologics?
When compared to other biologics, such as Stelara (ustekinumab), the dosing regimen for Skyrizi is different. Stelara is typically administered every 12 weeks for the treatment of psoriasis, while Skyrizi is administered every 12 weeks for the treatment of psoriasis and every 8 weeks for the treatment of Crohn's disease. This means that Skyrizi may require more frequent dosing than Stelara for the treatment of Crohn's disease. [3]
What are the potential side effects of Skyrizi?
As with any medication, Skyrizi can cause potential side effects, including injection site reactions, fatigue, headache, and increased liver enzymes. Patients should be monitored closely for these side effects, and the dosage may be adjusted or the medication discontinued if side effects are severe. [4]
Can Skyrizi be used with other medications?
Yes, Skyrizi can be used with other medications to treat psoriasis or Crohn's disease. However, patients should inform their healthcare provider about all medications they are taking, including over-the-counter medications and supplements, to ensure safe and effective treatment. [5]
When does patent exclusivity expire for Skyrizi?
The patent for Skyrizi is held by AbbVie, and it is expected to expire in 2037. This means that once the patent expires, generic versions of Skyrizi may become available. [6]
Sources:
[1] https://www.drugs.com/pro/skyrizi.html (accessed May 29, 2026)
[2] https://www.drugs.com/nda/2020/211124-skyrizi-abbvie-vftr-01.pdf (accessed May 29, 2026)
[3] https://www.drugs.com/comparison/stelara-and-skyrizi.html (accessed May 29, 2026)
[4] https://www.drugs.com/side-effects/skyrizi.html (accessed May 29, 2026)
[5] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211124s000lbl.pdf (accessed May 29, 2026)
[6] https://www.drugpatentwatch.com/patent/US-211124 (accessed May 29, 2026)